银诺医药-B (02591.HK)公布招股结果，香港公开发售接获5,341.66倍认购，一手(200股)中签率0.5%。国际发售录得10.67倍认购。发售价18.68港元，集资净额6.35亿港元。股份预期今日(15日)挂牌。
银诺医药为亚洲第一家及全球第三家商业化原研人源长效胰高血糖素样肽-1(GLP-1)受体激动剂公司，是次拟全球发售3,655.64万股H股，香港公开发售占10%。
银诺医药-B (02591.HK)公布招股结果，香港公开发售接获5,341.66倍认购，一手(200股)中签率0.5%。国际发售录得10.67倍认购。发售价18.68港元，集资净额6.35亿港元。股份预期今日(15日)挂牌。
银诺医药为亚洲第一家及全球第三家商业化原研人源长效胰高血糖素样肽-1(GLP-1)受体激动剂公司，是次拟全球发售3,655.64万股H股，香港公开发售占10%。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.